<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02005653</url>
  </required_header>
  <id_info>
    <org_study_id>IM0603-CEC-VCRC</org_study_id>
    <nct_id>NCT02005653</nct_id>
  </id_info>
  <brief_title>Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection</brief_title>
  <official_title>Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection: Double Blind Randomised Clinical Trial (RCT) to Study the Efficacy of Different Co-administration and Sequential Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indian Council of Medical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indian Council of Medical Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diethylcarbamazine (DEC) essentially a micro-filaricidal drug is given for 12 days as&#xD;
      standard treatment for the clearance of W. bancrofti infection. It takes about one year for&#xD;
      the individuals to completely clear the microfilaria from the blood. It takes another two to&#xD;
      four years to clear the antigen. The aim of the present study is to shorten the time taken&#xD;
      for clearing the Mf and antigen from the blood either by co-administration or sequential&#xD;
      administration of a macrofilaricidal drug, Albendazole or doxycycline. This study is a&#xD;
      randomized, double blind, controlled clinical trial to study the efficacy of these drug&#xD;
      combinations in complete clearance the Mf and antigen from the blood in shorter span of 180&#xD;
      days and 365 days respectively.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:&#xD;
&#xD;
      Lymphatic dwelling parasite W. bancrofti is the most common cause of secondary lymphoedema.&#xD;
      Till today, there is no effective treatment protocol for the complete clearance of W.&#xD;
      bancrofti infection, in a short duration of time.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      The investigators conducted a double blind RCT under field conditions recruiting 146&#xD;
      asymptomatic W. bancrofti infected individuals. Participants were randomly assigned one of&#xD;
      the four regimens for 12 days, DEC 300 mg + Doxycycline 100 mg co-administration or DEC 300&#xD;
      mg + Albendazole 400 mg co-administration or DEC 300 mg + Albendazole 400 mg sequential&#xD;
      administration or control regimen DEC 300 mg. Participants were followed up at 13, 26 and 52&#xD;
      weeks post-treatment for the clearance of infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete clearance of mf in 80% of the infected</measure>
    <time_frame>At 13th week (91 days) post therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete clearance Mf and complete clearance of antigen from the infected</measure>
    <time_frame>26 and 52 weeks post therapy</time_frame>
    <description>a)Complete clearance of Mf by 26 weeks (180 days) post therapy. b) Complete clearance of antigen by 52 weeks (365days) post therapy</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Filarial; Infestation</condition>
  <arm_group>
    <arm_group_label>DEC + ALB sequential</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diethylcarbamazine 300 mg tablet and albendazole 400 mg tablet at 30 days post treatment sequentially</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEC + ALB co-admin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diethylcarbamazine 300 mg tablet and albendazole 400 mg tablet per day given orally as single dose for 12 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEC + DOXY co-admin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diethylcarbamazine 300 mg tablet and Doxycycline 100 mg per day given orally as single dose for 12 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diethylcarbamazine (DEC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diethylcarbamazine 300 mg tablet as single dose orally per day for 12 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diethylcarbamazine</intervention_name>
    <description>Diethylcarbamazine 300 mg tablet as single dose per day for 12 days</description>
    <arm_group_label>DEC + ALB co-admin</arm_group_label>
    <arm_group_label>DEC + ALB sequential</arm_group_label>
    <arm_group_label>DEC + DOXY co-admin</arm_group_label>
    <arm_group_label>Diethylcarbamazine (DEC)</arm_group_label>
    <other_name>DEC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albendazole</intervention_name>
    <description>Experimental</description>
    <arm_group_label>DEC + ALB co-admin</arm_group_label>
    <arm_group_label>DEC + ALB sequential</arm_group_label>
    <other_name>Alb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Experimental</description>
    <arm_group_label>DEC + DOXY co-admin</arm_group_label>
    <other_name>Doxy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Residing in or around Pondicherry and adjoining Tamilnadu areas&#xD;
&#xD;
          -  Night blood microfilaria counts &gt; 10 mf/ml by membrane filtration&#xD;
&#xD;
          -  No history of treatment for filarial infection for the last two years at least&#xD;
&#xD;
          -  Willing for home visits by the staff of the center&#xD;
&#xD;
          -  Willing to give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body weight less than 30 kg&#xD;
&#xD;
          -  Hepatic or renal disease as evidenced by clinical or biochemical abnormalities. -&#xD;
             concurrent illness like hypertension, diabetes mellitus, cardiac conditions and&#xD;
             epilepsy requiring chronic medication&#xD;
&#xD;
          -  Psychiatric illness&#xD;
&#xD;
          -  Patients under tetracycline or doxycycline therapy&#xD;
&#xD;
          -  History of de-worming by albendazole or other anti-helminthic during last one year&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lourduraj J De Britto, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vector Control Research Centre, Indian Council of Medical Research, Pondicherry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vector Control Research Centre</name>
      <address>
        <city>Pondicherry</city>
        <zip>605006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>December 4, 2013</study_first_submitted>
  <study_first_submitted_qc>December 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <last_update_submitted>December 6, 2013</last_update_submitted>
  <last_update_submitted_qc>December 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indian Council of Medical Research</investigator_affiliation>
    <investigator_full_name>Lourduraj John De Britto</investigator_full_name>
    <investigator_title>Scientist-E (Medical)</investigator_title>
  </responsible_party>
  <keyword>Lymphatic filariasis</keyword>
  <keyword>W. bancrofti</keyword>
  <keyword>DEC</keyword>
  <keyword>Albendazole</keyword>
  <keyword>Doxycycline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parasitic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Albendazole</mesh_term>
    <mesh_term>Diethylcarbamazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

